SHANGHAI, May 13, 2016 /PRNewswire/ -- SiDanSai Biotechnology Co., Ltd. (SiDanSai) has recently released its first batch of Chimeric Antigen Receptor T (CAR-T) clinical data after completing 23 CAR-T trials of patients suffering from relapsed and refractory leukemia, of which 20 patients have achieved complete remission, proving an 87% complete remission rate, demonstrating the global leadership role of SiDanSai in CAR-T therapy.
Meanwhile, a SiDanSai delegation consisting of Dr. Jimmy Wei (CEO), Dr. Zhao Wu (President of Research and Development), and Dr. David Kapitula (Director of Production), was invited to visit Europe. After an inspection tour in France, Germany, the Netherlands and Belgium, various perspectives on technology export into Europe were thoroughly discussed by the SiDanSai delegation and several well-known cell therapy firms, with a view to establishing strategic cooperation or investment and expanding into the European market.
As part of its strategy for market expansion, SiDanSai has officially changed its English name to Innovative Cellular Therapeutics (ICT) (www.ictbio.com), reflecting the global vision of ICT in making continuous breakthroughs in cell therapy and benefiting human wellness. The Chinese name of SiDanSai remains unchanged.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/leading-chinese-car-t-cell-therapy-provider-sidansai-changes-name-to-ict-in-preparation-for-expansion-into-overseas-market-300268362.html
